tetano
Editor, Senior Moderator
Respir Med Res
. 2022 Mar 19;81:100903.
doi: 10.1016/j.resmer.2022.100903. Online ahead of print.
Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
Yuto Yasuda[SUP] 1 [/SUP], Yutaka Hirayama[SUP] 2 [/SUP], Kiyoshi Uemasu[SUP] 3 [/SUP], Soichi Arasawa[SUP] 4 [/SUP], Daisuke Iwashima[SUP] 3 [/SUP], Ken-Ichi Takahashi[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Remdesivir with dexamethasone and remdesivir with baricitinib are effective in coronavirus disease 2019 (COVID-19) patients. However, there has been few evidence regarding the efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic COVID-19 patients.
Methods: Consecutive patients who required oxygen therapy at the time of admission and received remdesivir and dexamethasone at Kishiwada City Hospital between March 1, 2021 and May 31, 2021 were retrospectively analyzed.
Results: A total of 90 patients were investigated, including 30 receiving a combination of remdesivir, dexamethasone, and baricitinib (baricitinib group) and 60 receiving remdesivir and dexamethasone (control group). The use of direct oral anticoagulants, the level of C-reactive protein, and chest X-ray abnormalities were significantly higher in the baricitinib group than in the control group. Patients in the baricitinib group recovered a median of four days faster than those in the control group (median, 7 days vs. 11 days; Gray's test, p < 0.001). The recovery rate was 90.0% in the baricitinib group and 63.3% in the control group (p = 0.011). Fine and Gray regression analysis showed that adjusted rate ratio for recovery with the baricitinib combination therapy was 5.26 (95% confidential interval, 1.99-13.9; p < 0.001). The incidence of new onset of bacterial infection was 6.7% in the baricitinib group and 16.7% in the control group (p = 0.324).
Conclusions: Our study suggests that the combination of baricitinib, dexamethasone, and remdesivir is effective and tolerable in hypoxic patients with COVID-19.
Keywords: Baricitinib; COVID-19; Dexamethasone; Remdesivir.
. 2022 Mar 19;81:100903.
doi: 10.1016/j.resmer.2022.100903. Online ahead of print.
Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
Yuto Yasuda[SUP] 1 [/SUP], Yutaka Hirayama[SUP] 2 [/SUP], Kiyoshi Uemasu[SUP] 3 [/SUP], Soichi Arasawa[SUP] 4 [/SUP], Daisuke Iwashima[SUP] 3 [/SUP], Ken-Ichi Takahashi[SUP] 3 [/SUP]
Affiliations
- PMID: 35316675
- DOI: 10.1016/j.resmer.2022.100903
Abstract
Background: Remdesivir with dexamethasone and remdesivir with baricitinib are effective in coronavirus disease 2019 (COVID-19) patients. However, there has been few evidence regarding the efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic COVID-19 patients.
Methods: Consecutive patients who required oxygen therapy at the time of admission and received remdesivir and dexamethasone at Kishiwada City Hospital between March 1, 2021 and May 31, 2021 were retrospectively analyzed.
Results: A total of 90 patients were investigated, including 30 receiving a combination of remdesivir, dexamethasone, and baricitinib (baricitinib group) and 60 receiving remdesivir and dexamethasone (control group). The use of direct oral anticoagulants, the level of C-reactive protein, and chest X-ray abnormalities were significantly higher in the baricitinib group than in the control group. Patients in the baricitinib group recovered a median of four days faster than those in the control group (median, 7 days vs. 11 days; Gray's test, p < 0.001). The recovery rate was 90.0% in the baricitinib group and 63.3% in the control group (p = 0.011). Fine and Gray regression analysis showed that adjusted rate ratio for recovery with the baricitinib combination therapy was 5.26 (95% confidential interval, 1.99-13.9; p < 0.001). The incidence of new onset of bacterial infection was 6.7% in the baricitinib group and 16.7% in the control group (p = 0.324).
Conclusions: Our study suggests that the combination of baricitinib, dexamethasone, and remdesivir is effective and tolerable in hypoxic patients with COVID-19.
Keywords: Baricitinib; COVID-19; Dexamethasone; Remdesivir.